Dopamine agonists in Parkinson’s disease

@article{Yamamoto2008DopamineAI,
  title={Dopamine agonists in Parkinson’s disease},
  author={Mitsutoshi Yamamoto and Anthony H V Schapira},
  journal={Expert Review of Neurotherapeutics},
  year={2008},
  volume={8},
  pages={671 - 677}
}
Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson’s disease (PD) throughout its course. As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications. As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant. The non-ergot dopamine agonists in particular have a good safety profile, although as with other… 
Are All Dopamine Agonists Essentially the Same?
TLDR
The brain distribution of dopamine receptors and their role in each of the dopaminergic pathways, the pharmacological profile of non-ergoline DAs and class-related adverse effects, as reported from post-marketing studies are discussed.
[Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
TLDR
The authors present their experience of prescription of rotigotine transdermal system in an open study of 30 patients with Parkinson's disease, finding a significant improvement of both motor and nonmotor symptoms.
Strategies for Parkinson’s disease care: prevention and management of motor fluctuations
TLDR
The use of levodopa revolutionized the pharmacological management of PD, multiple other agents and strategies have emerged with many demonstrable, albeit sometimes controversial, advantages to a ‘levodopa’ only approach.
What’s in the pipeline for the treatment of Parkinson’s disease?
TLDR
This review examines the current state of development of potential PD therapies, including dopaminergic therapies, modulators of adenosine and glutamate receptors, cell-based therapies, genetic therapies and device- based therapies.
Diet and medical foods in Parkinson’s disease
The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
TLDR
Adenosine is a neuromodulator that regulates the body’s response to dopamine and another neurotransmitter in the brain that is responsible for motoric, emotion, learning, and memory function and can reduce motoric symptoms in Parkinson's disease.
...
1
2
3
...

References

SHOWING 1-10 OF 71 REFERENCES
Dopamine agonists and neuroprotection in Parkinson's disease.
  • A. Schapira
  • Biology, Psychology
    European journal of neurology
  • 2002
TLDR
Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.
Pharmacology of dopamine agonists in the treatment of Parkinson’s disease
TLDR
Continuous administration of long-acting dopamine agonists may reverse the priming process initiated by l-dopa, markedly decreasing dyskinesia intensity with a minimal loss of antiparkinsonian activity, at least in MPTP-treated primates.
Treatment options in the modern management of Parkinson disease.
TLDR
Parenteral dopamine agonists and monoamine oxidase (MAO) B inhibitors offer effective relief of the motor features of PD in early and more advanced disease and are associated with a low risk for motor complications.
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
TLDR
The results indicate, to a certain extent, that the relative risk for onset of dopamine agonist-related fibrotic syndromes is lower particularly for pramipexole and lisuride, which have been available for more years than pramipesxole.
Novel pharmacological targets for the treatment of Parkinson's disease
TLDR
This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies.
Cabergoline in the treatment of early parkinson's disease
TLDR
The results of this study indicate that cabergoline treatment for up to 1 year is only marginally less effective than levodopa in the proportion of patients who can be treated in monotherapy.
Levodopa and the progression of Parkinson's disease.
TLDR
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter.
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
TLDR
It is indicated that pramipexole is safe and effective in the treatment of early Parkinson's disease and significantly reduced the severity of PD symptoms and signs compared with placebo.
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
TLDR
Clinical and imaging data both indicate that the early period after diagnosis is critical in terms of the rate of progression, implying that this is also a time of opportunity for interventions seeking to modify the course of the disease.
...
1
2
3
4
5
...